semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Postpoliomyelitis Syndrome Patients with Postpoliomyelitis Syndrome diagnosis confirmed over a year Electromyography test compatible with poliomyelitis Preserved ability to swallow medication Oral communication ability preserved Preserved ability to perform pedaling test in at least one lower limb affected by Postpoliomyelitis Syndrome Ability to understand information about the study and to document the decision about participating in the trial by signing the Informed Consent Form  History of intolerance to L-carnitine or piracetam Treatment with L-carnitine during the past 3 months Treatment with piracetam or any other nootropics pyrrolidone derivatives, during the past three months Anemia (hemoglobin reference range men 13 to 17 g/dL and women 12 to 15 g/dL) High level of glycated hemoglobin (> 7.0%) Electrolyte imbalance (hypokalaemia reference potassium concentration range: 3.5 to 5.6 mmol / L) Renal failure (creatinine reference range: 0.70 to 1.50 mg/dL) Urinary tract infection
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Scar Ages 50 (Both Male & Female) Non-smoker having quit at least 3 months prior to enrollment Non-diabetic Non-pregnant or non-breastfeeding verbal assent If a female subject of childbearing age misses her menstrual period after the start of the study, she will inform the investigators and be given a pregnancy test to ensure, for safety reasons, that she is not pregnant. If she is pregnant, she will discontinue participation in the study No current use of OTC medications or other form of supplements containing vitamin-E  Diabetes or HIV diagnosis Alcohol or drug abuse unable to provide informed consent Therapeutically anti-coagulated Prisoner Currently prescribed immunosuppressant medication
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Post Traumatic Stress Disorder All parents of children admitted to paediatric intensive care for over 12 hours  Parents deemed unsuitable for the study by the responsible consultant. This will families where a child's condition is suspected to result from non-accidental injury or where withdrawal of care is being discussed due to a child's critical condition. Families will be excluded if their child died during or after admission, as these families are already followed up routinely
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hereditary Inclusion Body Myopathy (HIBM) GNE Myopathy Subject is 18-70 years, either gender, inclusive Subject has a diagnosis of HIBM (or IBM2, GNE myopathy, DMRV or Nonaka myopathy) based upon a consistent clinical course and identification of 2 GNE mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study Subject must be willing to stop any treatment with ManNAc, sialic acid, IVIG, and/or other supplements containing sialic acid (eg, St John s wort, sialyllactose) 30 days prior to randomization and remain off such treatment for the duration of the trial Subject has the ability to travel to the NIH Clinical Center (CC) for admissions Subject (if a woman of reproductive age) must be willing to use an effective method of contraception for the duration of the trial Subject provides written informed consent  Subject has a severe disease manifestation that would interfere with the ability to comply with the requirements of this protocol Subject has a psychiatric illness or neurological disease that would interfere with the ability to comply with the requirements of this protocol. This includes, but is not limited to, uncontrolled/untreated psychotic depression, bipolar disorder, schizophrenia, substance abuse or dependence, antisocial personality disorder, or panic disorder Subject has hepatic laboratory parameters (AST, ALT, GGTP), or renal laboratory parameters (creatinine, BUN) greater than 3 times the upper limit of normal Subject has a QTcB >450 msec (males) or QTcB >470 msec (females) Subject is anemic (defined as two standard deviations below normal for age and gender) Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires immediate surgical intervention Subject is pregnant or breastfeeding at any time during the study Subject has received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 4 weeks of initial screening Subject has a hypersensitivity to ManNAc or in the judgment of the investigator, has a condition that places the subject at increased risk for adverse effects
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Provision of informed consent 2. Pathological confirmation of breast cancer 3. Tumor stage(TNM):T2-4bN0-3M0 4. ER(+) and/or PR(+). 5. Premenopausal woman. 6. Age≥40 years 7. Measurable disease as per 8. Karnofsky≥70 9. Laboratory PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl ALT and AST<2*ULN  Presence of metastatic disease. 2. Inflammatory breast cancer. 3. Bilateral breast cancer. 4. previous chemotherapy or hormonal therapy for current breast neoplasm. 5. other malignant tumor (concurrent or previous). 6. Pregnant woman. 7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex. 8. Any severe systemic disease contraindicating chemotherapy
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 5.0-999.0,  Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE) Thymidine Phosphorylase (TP) defect: 1. homozygous or 2. compound heterozygous mutations in the TYMP gene, and/or 3. TP enzyme activity of <20% of normal. 2. Increased plasma Thd > 3 micromole/L 3. Increased plasma dUrd > 7.5 micromole/L 4. Age requirement of at least 5 years of age  Participation in an interventional (study medication or other experimental intervention) study (within 1 month of participation in this study). 2. Unable to travel to site for research visits. 3. Unwillingness to sign informed consent form. 4. Substance abuser
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Depressive Symptoms B-RICH Phase I, Pilot 1. Age 18 or older 2. Endorse one item on the PHQ-2 3. Able to be contacted by phone 4. Able to participate in the six, weekly 90-120 minute sessions of the Resiliency Classes 5. English or Spanish speaker B-RICH, Phase I Pilot  Under age 18 years 2. Endorse no items on PHQ-2 screener 3. PHQ-8 score of 15 or greater on the baseline interview 3) Unable to be contacted by phone 4) Unable to attend the weekly resiliency classes B-RICH Phase II, Randomized Trial 1. Age 18 or older 2. Endorse one of the first two items on the PHQ-8: "In the past two weeks, how often have you been bothered by 1) little interest or pleasure in doing things, 2) feeling down depressed or hopeless." 3. Able to be contacted by phone (voice or text message), e-mail, or Facebook. 4. Able to participate in the seven, weekly 90-120 minute sessions of the Resiliency Classes 5. English or Spanish speaker B-RICH Phase II, Randomized Trial Under age 18 years 2. PHQ-8 score of 20 or greater on the baseline interview 3. PHQ-8 score of 15 or greater and not currently in care and unwilling to get a referral for care 4. Currently homeless 5. Has a prior diagnosis of Bipolar Disorder 6. Has a prior diagnosis of Schizophrenia 7. Current alcohol and substance abuse 8. Unable to attend the weekly resiliency classes 9. Does not currently have a phone, an email address, or a Facebook profile
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Myositis Muscular Disorders, Atrophic Any adult patient referred for an MR scan with a suspected clinical diagnosis of myopathy  Patient unable or unwilling to have an MR scan Standard MR will apply
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  Myasthenia Gravis 12 to 65 years； 2. Myasthenia gravis: 1. Patients who are diagnosed as generalized or ocular myasthenia gravis 2. have experienced extended thymectomy (including thymic hyperplasia and thymoma)， no significant complications in 6 months after operation , and does not received any immunosuppressants or glucocorticoids treatments. 3. do not applied in plasmapheresis or immunoglobulins treatment during 3 months . 4. women of child-bearing period do not have a plan of pregnant for at least 3 year. 5. Written consent of the patient, after informing  The liver , kidney or glycometabolic function is abnormal 2. Seriously complications, such as infection or symptom in central nervous system, 3. The patients who suffering from malignancy or a history of malignancy, a variety of sexually transmitted diseases and HIV infection, tuberculosis infection, and other condition which need to prohibit the use of immunosuppressive patients. 4. Be allergic to leflunomide, azathioprine 5. Pregnant or suckling period woman 6. Accompanied with mental disorders and have difficult to communication 7. Experienced myasthenia crisis in 3 months. 8. suffering from clear cardiopulmonary functional and brain abnormalities 9. Have a history of refractory hypertension or peptic ulcer . 10. One of the white blood cells, hemoglobin, and platelet count obvious abnormalities
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Vestibulodynia non pregnant women between 18-35 naïve to HCs or other hormonal medications Patients able to provide Informed Consent and complete questionnaires Patient intends to use HCs for at least one year On exam before initiation of HCs, patient does not have primary PVD, pelvic floor hypertonicity, vaginismus or congenital abnormalities Patient will be available for follow up appointments Patient is willing to undergo gynecologic examination, if dyspareunia develops  Patients with endocrine disturbances (including PCOS), liver diseases and eating disorders Patients who suffer from Hypertension, Migraine with aura or clotting disturbances Patients that experience pain with intercourse or tampon insertion Patients that have other contraindications for HCs use
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Life Stress Fatigue Pain Quality of Life Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the visit for the women of reproductive age Older than 30 years and younger than 65 years BMI ≤ 30 Score greater than 30 on the Cohen perceived stress scale PSS 14 Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits) Presenting an impact of stress on at least one of the following domains pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test Stable professional activity since at least 1 year  Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment Pregnant and/or breast-feeding women Any person who does not satisfy by definition the criteria Adult protected by the law Any history of psychiatric disease Any pathology in progress or active in the previous month Any administration of a dietary supplement in progress or in the previous month Any subject who within the 3 months following is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intimate Partner Violence She is 18 or older She is currently court supervision at Bronx Community Solutions or a drug treatment court or she is currently on probation She reports using any illicit drug or drinking 4 or more alcoholic drinks in a 6-hour period in the past 90 days or she has been in alcohol or drug treatment in the past 6 months OR if she report attending any drug or alcohol treatment in the past 6 months She reports having had an ongoing intimate, dating or sexual relationship with a male or female partner that lasted 3 or more months in the past year She lives within a 90-minute commute of 125th and Broadway  Ability to speak and understand English is not sufficient to participate in assessments or intervention sessions Inability to complete informed consent process due to a psychiatric or cognitive impairment The participant is unwilling or unable to commit to completing all the activities in the study